N-Acetylcysteine Amide

Phase 3Small molecule

NNacuity Pharmaceuticals, Inc.

N-Acetylcysteine Amide is one of 39 small molecule programs targeting Cystinosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CystinosisActive, not recruiting

Retinitis PigmentosaActive, not recruiting

Retinitis Pigmentosa (RP)Not yet recruiting

CystinosisPreclinical

Active, not recruiting

Retinitis PigmentosaPhase 3

Active, not recruiting

Retinitis Pigmentosa (RP)Phase 3

Not yet recruiting

Competition

Competitive Landscape

73 competitors in Retinitis Pigmentosa

#DrugCompanyPhaseTrials

Cysteine Hydrochloride

Novartis

Phase 3

1 2

Minocin

TTriax

Phase 3

2 3

Aquasol a

BBandim Health Project

Phase 3

2 4

Aquasol E

NNational Eye Institute (NEI)

Phase 3

1 5

Depakote

AbbVie

Phase 2

2 6

Eylea

Regeneron

Phase 2

1 7

Alphagan

AbbVie

Phase 2

1 8

N-Acetylcysteine Amide

NNacuity Pharmaceuticals, Inc.

Phase 3

2 9

Lutein

NNational Eye Institute (NEI)

Phase 3

2 10

Levodopa-Carbidopa

AbbVie

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

PreclinicalActive, not recruiting

Cystinosis

NCT05994534

Q3 2029

Phase 3Not yet recruiting

Retinitis Pigmentosa (RP)

NCT07290530

Clinical

Trials by Indication[1]

Retinitis Pigmentosa (RP)1 trial

A 24-Month, Randomized, Double-Masked, Placebo-Controlled Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome

Not yet recruiting·NNacuity Pharmaceuticals, Inc.·Phase 3·NCT07290530·80 enrolled

Cystinosis1 trial

A Phase 1/2 Pharmacokinetic and Pharmacodynamic Study of NPI-001 Oral Solution Compared to Cysteamine Bitartrate in Cystinosis Patients

Active, not recruiting·NNacuity Pharmaceuticals, Inc.·Preclinical·NCT05994534·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for N-Acetylcysteine Amide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — N-Acetylcysteine Amide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for N-Acetylcysteine Amide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nacuity Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNacuity Pharmaceuticals, Inc.

N-Acetylcysteine Amide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q3 2029

Trials by Indication[1]

Retinitis Pigmentosa (RP)1 trial

Cystinosis1 trial

References

Drug Info

Quick Facts

Related News